Abortion Pill Inventor Etienne-Emile Baulieu Dies At 98
Rome:
French scientist Etienne-Emile Baulieu, best known as the inventor of the abortion pill, died on Friday aged 98 at his home in Paris, his institute said in a statement.
Both a doctor and a researcher, Baulieu was known around the world for the scientific, medical and social significance of his work on steroid hormones.
"His research was guided by his attachment to the progress made possible by science, his commitment to women's freedom, and his desire to enable everyone to live better, longer lives," the Institut Baulieu said in the statement posted on its website.
Born Etienne Blum in Strasbourg on Dec. 12, 1926, he took the name "Emile Baulieu" when he joined the French Resistance against the Nazi occupation at the age of 15.
An endocrinologist with a doctorate in medicine completed in 1955 and one in science eight years later, in 1963 Baulieu founded a pioneering research unit working on hormones at INSERM, the French institute for health and medical research. He remained as head of the unit until 1997.
He is best known for his development, in 1982, of RU 486, the so-called "abortion pill" that changed the lives of millions of women throughout the world, offering them the possibility of voluntary medical termination of pregnancy, in physical and psychological safety.
The Institut Baulieu said it was "a non-invasive method, less aggressive and less delayed than surgery," noting that following his discovery the researcher faced fierce criticism and even threats from opponents of women's abortion rights.
"Even today, access to this method is opposed, banned in some countries, and is currently being challenged in the United States, where it is the most widely used abortion method," the institute added.
Baulieu's research into DHEA, a hormone whose secretion and anti-aging activity he had discovered, led him to work on neurosteroids -- or steroids of the nervous system. He also developed an original treatment to combat depression, for which a clinical trial is currently underway in several university hospitals.
In 2008, he founded the Institut Baulieu to understand, prevent and treat neurodegenerative diseases such as Alzheimer's.
Honored with the grand crosses of the Légion d'honneur (legion of honor) and the Ordre national du Mérite (national order of merit), he was elected to the French Academy of Sciences in 1982, which he chaired in 2003 and 2004.
He was a member of the national advisory committee on life sciences and health (1996-2002) and received numerous awards, both in France and abroad.
French President Emmanuel Macron paid tribute to Baulieu in a post on X, calling him "a beacon of courage" and "a progressive mind who enabled women to win their freedom."
"Few French people have changed the world to such an extent," he added.
After the death of his first wife, Yolande Compagnon, he remarried, to Simone Harari Baulieu. He is survived by three children, eight grandchildren and nine great-grandchildren, his institute said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
THIS common condition may speed up Alzheimer's disease: Experts recommend a simple blood test to determine it
A recent study presented at the European Academy of Neurology Congress 2025 reveals that a blood test could predict rapid cognitive decline in early Alzheimer's patients. Researchers at the University of Brescia found insulin resistance, measured by the TyG index, significantly accelerates the disease's progression. Alzheimer's disease, which is the most common type of dementia, is on the rise. About 57 million people had dementia worldwide in 2021, and the numbers are escalating. This progressive neurodegenerative disorder affects the quality of life, even impacting daily activities, and hence, early diagnosis is crucial. Researchers have now found that a simple blood test may soon help doctors predict which patients with early Alzheimer's disease are most at risk of rapid cognitive decline. They also found that a common condition related to metabolic disorders could dramatically accelerate the disease. The research was led by neurologists at the University of Brescia in Italy and was presented at the European Academy of Neurology (EAN) Congress 2025. Common condition linked to accelerated Alzheimer's disease The common condition in question is insulin resistance . The researchers looked at the records of 315 non-diabetic patients with cognitive deficits, including 200 with biologically confirmed Alzheimer's disease. All participants underwent a TyG index assessment and were followed clinically over three years. The researchers found that the patients in the highest third of the TyG index within the Mild Cognitive Impairment-AD subgroup declined significantly faster than those with lower readings, losing more than 2.5 points per year on the widely used Mini-Mental State Examination. The ratio for rapid progression was 4.08 (95% CI 1.06–15.73), which is a fourfold increase in risk. 'Once mild cognitive impairment is diagnosed, families always ask how fast it will progress. Our data show that a simple metabolic marker available in every hospital laboratory can help identify more vulnerable subjects who may be suitable candidates for targeted therapy or specific intervention strategies,' lead investigator Dr Bianca Gumina said in a statement. Impact of insulin resistance on Alzheimer's disease Though previous research has shown the association between insulin resistance and Alzheimer's disease , its role in how quickly the condition progresses has not been much explored. This recent study looked into insulin resistance's impact during the prodromal mild cognitive impairment (MCI) stage, when patients follow highly variable trajectories. What is insulin resistance Insulin resistance is a condition where the body's cells do not respond properly to insulin. Insulin is a hormone produced by the pancreas that helps glucose (sugar) enter cells for energy. To compensate, the pancreas produces more insulin, but over time, this can lead to elevated blood sugar levels (hyperglycemia), increasing the risk of type 2 diabetes and other serious health conditions. The study The researchers used the TyG index, a simple and affordable way to measure insulin resistance, to see if metabolic problems could help predict how quickly cognitive decline happens after diagnosis. 'We were surprised to see the effect only in the Alzheimer's spectrum and not in other neurodegenerative diseases. It suggests a disease-specific vulnerability to metabolic stress during the prodromal window, when interventions may still change the trajectory', Dr Gumina added. Salman Khan Drops Health Bombshell on National TV The researchers at the University of Brescia, led by Professor Padovani and Professor Pilotto, found that high TyG was also associated with blood–brain barrier disruption and cardiovascular risk factors. However, it showed no interaction with the APOE ε4 genotype, and hinted that metabolic and genetic risks may act through distinct pathways. 'If targeting metabolism can delay progression, we will have a readily modifiable target that works alongside emerging disease-modifying drugs', Dr Gumina concluded. One step to a healthier you—join Times Health+ Yoga and feel the change
Time of India
15 hours ago
- Time of India
Crunchy culprit: Study shows how to tackle acrylamide in French fries
Ahmedabad: That satisfying crunch in French fries and toasted sandwiches might be coming at a hidden cost. The crunch is attributed to a substance identified as acrylamide, which gives the distinct brown colour to deep-fried foods. According to several studies, the substance is linked to various gastrointestinal (GI) issues and can even lead to cancer if consumed very frequently. Research carried out at IIT Gandhinagar (IIT-Gn) addressed the issue by using amino acid adducts (AAA). The findings were published in the form of a paper titled 'Sequestration of acrylamide as amino acid-acrylamide adducts mitigates cellular stress in human gastrointestinal cell lines' recently in the journal, Food and Function, of the UK-based Royal Society of Chemistry. The authors were Axita Patel and Prof Bhaskar Datta. "Starchy foods exposed to frying, baking or roasting are vulnerable to forming acrylamide through a chemical reaction between a natural sugar (glucose) and an amino acid (asparagine). This reaction is identified as the Maillard reaction. Acrylamide is commonly found in fried potato products (French fries, chips), biscuits, toast, cookies and coffee, to name a few," said Prof Datta. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Irish homeowners eligible for solar 'bonus' if they live in these eircodes Activ8 Learn More Undo "Before its association with food, it was always associated with the chemical industry as a versatile petrochemical. " The researchers said that the rise in foods prepared at high temperatures has resulted in higher exposure to acrylamide. Acrylamide's toxic effects create oxidative stress, which affects cells in the GI tract, causing inflammation, tissue damage and even cancer. Prof Datta said that to counter acrylamide, they employed AAA. The interaction of AAA as a 'treatment agent' indicated significantly lower production of acrylamide. The team used amino acids lysine, glycine, cysteine and methionine to form stable adducts to capture acrylamide. The team is also working on sprinkle-type formulations that can be applied to raw potatoes before frying. "The study opens a new way to look at 'capturing' acrylamide to reduce its harmful effects through specific amino acids and also underlines the reason for avoiding fried starchy food not only for cholesterol but also for acrylamide. Regular consumption of antioxidants is also important," said Prof Datta. He gave a practical tip to French fries enthusiasts. "As evident in our work, a simple blanching of potatoes (briefly submerged in very hot water and then quickly cooled in ice water) before they are fried can reduce the acrylamide content," he said.
Time of India
a day ago
- Time of India
French scientists find new blood type in Guadeloupe woman
Basse-Terre: A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed "Gwada negative," France's blood supply agency has announced. The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on Friday. "The EFS has just discovered the 48th blood group system in the world!" the agency said in a statement on social network LinkedIn. "This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT)." The scientific association had until now recognised 47 blood group systems . Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a "very unusual" antibody was first found in the patient in 2011. However, resources at the time did not allow for further research, he added. Scientists were finally able to unravel the mystery in 2019 thanks to " high-throughput DNA sequencing ", which highlighted a genetic mutation, Peyrard said. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said. This woman "is undoubtedly the only known case in the world," said the expert. "She is the only person in the world who is compatible with herself," he said. Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene. The name "Gwada negative", which refers to the patient's origins and "sounds good in all languages", has been popular with the experts, said Peyrard. The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing the discovery of new blood groups has accelerated in recent years. Peyrard and colleagues are now hoping to find other people with the same blood group. "Discovering new blood groups means offering patients with rare blood types a better level of care," the EFS said. cre-tmt-as/yad
